Following the study, the FDA approved the use of Tremfya to treat moderately to severely active ulcerative colitis. In September 2024, the University of Chicago Medicine became the first hospital in ...

DelveInsight's "ENTYVIO Market Size, Forecast, and Market Insight Report" highlights the details around ENTYVIO, a gut-selective biologic developed by Takeda Pharmaceutical. The report provides ...

Brian Austin Green is on the road to recovery after undergoing emergency surgery for a perforated appendix: 'It’s not an easy ...

The University of Central Lancashire is co-leading the first and largest human trial of its kind. A study found that patients with mild-to-moderate ulcerative colitis who drank 130ml of diluted Montmo ...

The overlap of biologics during medication switches is common in routine care of patients with IBD and isn’t linked to a ...

Although the appendix is generally believed to be a vestigial organ, there is growing evidence pointing to its possible role in modulating gut immunity and microbial homoeostasis.1,2 These roles have ...

The Crohn's and Colitis Foundation is committed to finding cures for Crohn's disease and ulcerative colitis as they also work ...

In this new study, researchers found that the group taking probiotics had not only an overall reduction in negative emotions, ...

In April 2025, Janssen Research & Development, LLC announced a study is to evaluate the efficacy, including clinical ...

A significant proportion of children newly diagnosed with IBD present with anaemia, and many of them remain anaemic even ...

ThirtyFiveBio Limited, a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of gastrointestinal (GI) disease, today ...